Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.4%

5 terminated/withdrawn out of 48 trials

Success Rate

80.8%

-5.7% vs industry average

Late-Stage Pipeline

13%

6 trials in Phase 3/4

Results Transparency

38%

8 of 21 completed trials have results

Key Signals

10 recruiting8 with results

Enrollment Performance

Analytics

Phase 2

26(60.5%)

Early Phase 1

7(16.3%)

Phase 3

6(14.0%)

Phase 1

2(4.7%)

N/A

2(4.7%)

43Total

Phase 2(26)

Early Phase 1(7)

Phase 3(6)

Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (48)

Showing 20 of 48 trials

NCT07237256Phase 3Recruiting

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Role: collaborator

NCT05512364Phase 3Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Role: collaborator

NCT05296746Phase 2Active Not Recruiting

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Role: lead

NCT03609047Phase 2Active Not Recruiting

Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Role: collaborator

NCT05982093Phase 2Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Role: lead

NCT06764186Phase 3Active Not Recruiting

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Role: collaborator

NCT07371585Phase 2Recruiting

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

Role: lead

NCT04253561Phase 1Completed

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

Role: lead

NCT05340413Phase 2Completed

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Role: lead

NCT06446882Not ApplicableRecruiting

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

Role: collaborator

NCT02947685Phase 3Active Not Recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Role: collaborator

NCT04578106Phase 2Terminated

Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

Role: collaborator

NCT06078384Phase 2Recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Role: collaborator

NCT03802604Early Phase 1Completed

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Role: lead

NCT04257162Not ApplicableActive Not Recruiting

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)

Role: lead

NCT04759248Phase 2Active Not Recruiting

Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Role: lead

NCT04497285Active Not Recruiting

Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer

Role: lead

NCT05885009Recruiting

Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)

Role: lead

NCT04251169Phase 2Terminated

Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

Role: lead

NCT06991946Recruiting

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

Role: lead